Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen

Gene Therapy

Volumn 7, Issue 24, 2000, Pages 2080-2086

  Song, W ^a   Tong, Y ^a   Carpenter, H ^a   Kong, H L ^a   Crystal, R G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adenovirus; Dendritic cells; Gene therapy; T cell memory; Tumor immunity

Indexed keywords

BETA GALACTOSIDASE; CANCER VACCINE; TUMOR ANTIGEN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER INHIBITION; CELLULAR IMMUNITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA MODIFICATION; IMMUNOLOGICAL MEMORY; IN VIVO STUDY; LUNG TUMOR; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SURVIVAL TIME; TUMOR IMMUNITY; TUMOR MODEL;

ADENOVIRIDAE; ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; BETA-GALACTOSIDASE; COLONIC NEOPLASMS; DENDRITIC CELLS; GENE THERAPY; GENETIC VECTORS; IMMUNOLOGIC MEMORY; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES;

EID: 0034515463     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301336     Document Type: Article

References (45)

1. Cancer vaccines
2. Cancer antigens: Immune recognition of self and altered self
3. Human tumor antigens recognized by T lymphocytes
4. The dendritic cell system and its role in immunogenicity
5. Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy?
6. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity
7. Dendritic cells as adjuvants for immune-mediated resistance to tumors
8. Dendritic cells and the control of immunity
9. Transfer of genes to humans: Early lessons and obstacles to success
10. Gene therapy - Promises, problems and prospects
11. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
12. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
13. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
14. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
15. Induction of antitumor immunity using bone marrow-generated dendritic cells
16. Therapy of murine tumors with tumor peptidepulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
17. Vaccination of melanoma patients with peptideor tumor lysate-pulsed dendritic cells
18. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1)
19. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene
20. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
21. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
22. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells
23. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
24. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination
25. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTL
26. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection
27. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression
28. d by cytolytic T cells
29. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection
30. Tumor escape from immune recognition. Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen
31. Antigen presentation to cytotoxic T lymphocytes in vivo
32. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation
33. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
34. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen
35. Specificity of the mouse cytotoxic T lymphocyte response to adenovirus 5. E1a is immunodominant in H-2b, but not in H-2d or H-2k mice
36. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
37. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo
38. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium
39. Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector
40. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
41. Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes
42. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype
43. Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors
44. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor
45. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples